NCT02393248: Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies

NCT02393248
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: FGFR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Immunotherapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must harbor an FGF/FGFR mutation
Exclusions: 
https://ClinicalTrials.gov/show/NCT02393248

Comments are closed.

Up ↑